

18. Pharmaceutical composition according to claim 16 or 17, wherein the IL-1R3 mediated disease is selected from the group consisting of lung cancer, non-small cell lung (NSCL) cancer, bronchioloalviolar cell lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, gastric cancer, colon cancer, breast cancer, or uterine cancer.
19. Use of humanized antibody according to claims 1 to 15 or pharmaceutical composition according to claims 16-18, in the manufacture of a medicament for the treatment of cancer, wherein the medicament is to be used in combination with one or more cytotoxic, cytostatic or targeted anti-cancer compounds.